First Line B plus R in Elderly Patients with Indolent Non-Hodgkin's Lymphoma and Mantle Cell Lymphoma: A Real- World Experience

被引：0
|
作者：
Kotchetkov, Rouslan [1 ]
Susman, David [2 ]
Gerard, Lauren M. [3 ]
Dimaria, Erica [4 ]
Nay, Derek [5 ]
Prica, Anca [6 ]
机构：
[1] Univ Toronto, Med, Toronto, ON, Canada
[2] Univ Western Ontario, Med, London, ON, Canada
[3] Royal Victoria Hosp, Med Oncol, Barrie, ON, Canada
[4] Royal Victoria Hlth Ctr, Med Oncol, Barrie, ON, Canada
[5] Royal Victoria Hosp, Barrie, ON, Canada
[6] Princess Margaret Canc Ctr, Dept Med Oncol & Hematol, Toronto, ON, Canada
来源：
BLOOD | 2021年 / 138卷
关键词：
D O I：
10.1182/blood-2021-144888
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4519
引用
收藏
页数：5
相关论文
共 50 条
  • [31] Real-world healthcare resource utilization in patients with indolent non-Hodgkin lymphoma: differences between patients treated with first-line ibrutinib or bendamustine plus rituximab
    Irwin, Debra E.
    Wilson, Kathleen
    Hoehn, Gerard
    Min, Stella
    Szabo, Erika
    CURRENT MEDICAL RESEARCH AND OPINION, 2020, 36 (03) : 439 - 444
  • [32] B cell non-Hodgkin's lymphoma: rituximab safety experience
    Mohrbacher, A
    ARTHRITIS RESEARCH & THERAPY, 2005, 7 (Suppl 3) : S19 - S25
  • [33] B cell non-Hodgkin's lymphoma: rituximab safety experience
    Ann Mohrbacher
    Arthritis Research & Therapy, 7
  • [34] The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma
    Friedberg, Jonathan W.
    Vose, Julie M.
    Kelly, Jennifer L.
    Young, Faith
    Bernstein, Steven H.
    Peterson, Derick
    Rich, Lynn
    Blumel, Susan
    Proia, Nicole K.
    Liesveld, Jane
    Fisher, Richard I.
    Armitage, James O.
    Grant, Steven
    Leonard, John P.
    BLOOD, 2011, 117 (10) : 2807 - 2812
  • [35] Promising activity of the proteasome inhibitor bortezomib (velcade) in the treatment of indolent non-Hodgkin's lymphoma and mantle cell lymphoma.
    O'Connor, O
    Wright, J
    Moskowitz, CH
    Muzzy, J
    MacGregor-Cortelli, B
    Hamlin, P
    Straus, D
    Trehu, E
    Schenkein, DP
    Zelenetz, AD
    BLOOD, 2003, 102 (11) : 636A - 636A
  • [36] Coping and Perception of Prognosis in Patients With Indolent Non-Hodgkin's Lymphoma
    Newcomb, Richard A.
    Johnson, P. Connor
    Yang, Daniel
    Holmbeck, Katherine
    Choe, Joanna
    Nabily, Anisa
    Lark, Porsha
    Dhawale, Tejaswini
    Amonoo, Hermioni L.
    El-Jawahri, Areej
    ONCOLOGIST, 2023, : 441 - 449
  • [37] An open-label phase 2 trial of entospletinib in indolent non-Hodgkin lymphoma and mantle cell lymphoma
    Andorsky, David J.
    Kolibaba, Kathryn S.
    Assouline, Sarit
    Forero-Torres, Andres
    Jones, Vicky
    Klein, Leonard M.
    Patel-Donnelly, Dipti
    Smith, Mitchell
    Ye, Wei
    Shi, Wen
    Yasenchak, Christopher A.
    Sharman, Jeff P.
    BRITISH JOURNAL OF HAEMATOLOGY, 2019, 184 (02) : 215 - 222
  • [38] NON-HODGKIN'S LYMPHOMA (NHL) IN ELDERLY PATIENTS: A 15 YEAR EXPERIENCE
    Sabbioni, R.
    Zuliani, S.
    Pasini, F.
    Manno, P.
    Merlin, F.
    Nortilli, R.
    Sava, T.
    Cetto, G. L.
    ANNALS OF ONCOLOGY, 2004, 15 : 78 - 79
  • [39] Glofitamab in Aggressive B Non-Hodgkin Lymphoma (B-NHL): A Real World Experience
    Chan, Thomas
    Kwong, Yok Lam
    Tse, Eric
    BLOOD, 2023, 142
  • [40] Elderly aggressive-histology non-Hodgkin's lymphoma: First-line VNCOP-B regimen experience on 350 patients
    Zinzani, PL
    Storti, S
    Zaccaria, A
    Moretti, L
    Magagnoli, M
    Pavone, E
    Gentilini, P
    Guardigni, L
    Gobbi, M
    Fattori, PP
    Falini, B
    Lauta, VM
    Bendandi, M
    Gherlinzoni, F
    De Renzo, A
    Zaja, F
    Mazza, P
    Volpe, E
    Bocchia, M
    Aitini, E
    Tabanelli, M
    Leone, G
    Tura, S
    BLOOD, 1999, 94 (01) : 33 - 38
12345